Adcendo ApS Announces Significant Milestones in Antibody-Drug Conjugates Development

Advancements in Antibody-Drug Conjugates by Adcendo ApS

Adcendo ApS, a pioneering biotechnology company based in Copenhagen, Denmark, has recently marked significant milestones in its pipeline of first- and best-in-class antibody-drug conjugates (ADCs). The firm, known for its dedication to treating cancers with high unmet medical needs, has made headlines with its latest updates regarding its ADCs, notably ADCE-T02, ADCE-D01, and ADCE-B05.

Progressing Research Fields

The ADC, ADCE-T02, is rapidly advancing into the cohort expansion phase of the Tiffany-01 study, aiming at treating patients with advanced solid tumors. This ADC specifically targets tissue factor (TF), which is typically overexpressed in numerous solid tumors, including head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma, yet shows limited expression in normal tissues. By targeting this crucial aspect, Adcendo hopes to provide more effective treatment options for affected patients.

Initially evaluated as a monotherapy, ADCE-T02 is currently part of a Phase I clinical trial, Tiffany-01 (NCT06597721), with patients newly enrolled across varying tumor types. The ongoing trial aims to assess dosage optimization while gathering crucial data regarding safety, anti-tumor activity, and the durability of responses. Preliminary results from these trials are anticipated, creating a roadmap for potential therapeutic use in multiple solid tumor types.

Highlighting Research Achievements

Adcendo has also showcased significant preclinical findings regarding ADCE-T02 at the prestigious American Association for Cancer Research (AACR) 2026 Annual Meeting. The findings were selected for a poster presentation that demonstrates its strong efficacy in preclinical models of head and neck squamous cell carcinoma. Entitled "ADCE-T02 - A clinical stage antibody drug conjugate targeting tissue factor demonstrates strong efficacy in preclinical models of head and neck squamous cell carcinoma," this abstract has drawn attention for its promising implications in the clinical development of ADCs.

Moreover, a detailed manuscript has been published in the AACR journal, Molecular Cancer Therapeutics. This document, titled "ADCE-T02 - A Next Generation Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability," emphasizes the unique design characteristics of ADCE-T02, showcasing impressive in vivo efficacy across various preclinical models without demonstrating the concerning toxicities often associated with cancer treatments.

Regulatory Updates and New Trials

In a significant regulatory achievement, Adcendo's ADC, ADCE-D01, received the Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), establishing it as the first ADC targeting uPARAP — a receptor that shows potential therapeutic promise primarily in soft tissue sarcoma patients. The firm targets this rare cancer through the ongoing Phase I ADCElerate1 trial (NCT06797999).

Furthermore, the company marked another important milestone with the first patient being dosed in the Phase I trial of ADCE-B05, which is designated for a novel, undisclosed target overexpressed in squamous tumors. This trial is pivotal as it explores new avenues against aggressive cancer variations, addressing patients' critical needs.

Vision for the Future

Dr. Lone Ottesen, Adcendo’s Chief Medical Officer, expressed enthusiasm regarding the notable achievements accomplished across its ADC pipeline. The company aims to expedite its clinical programs and provide innovative cancer treatment solutions, funded significantly by its recent $75 million Series C financing round. The focus remains on offering new options to patients suffering from cancers that are currently underserved in terms of effective treatment possibilities.

Adcendo ApS continues to leverage its expertise and innovative strategies to develop next-generation cancer therapies, with several ADC candidates in the clinical pipeline. As it progresses through clinical trials, the company is poised to make impactful strides in oncology, aligning its goals to improve patient outcomes significantly.

For more information on Adcendo ApS and its promising pipeline, please visit their website or follow their updates on LinkedIn.